Skip to main content

Table 1 The results of allogeneic CAR-T cell infusion after allogeneic transplantation in B cell malignancies

From: Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies

Author No. of patients Disease Activation motif of CAR Dose of infused CAR-T No. of GVHD Toxicities Outcomes
Kochenderfer et al. 10 CLL, DLBCL, and MCL 28 Between 0.4 × 106/kg and 7.8 × 106/kg No Fatigue, fever, and hypotension 1 CR, 1 PR, and 6 with stable disease
Cruz et al. 8 CLL and ALL 28 Escalation schedule of 1.5 × 107/m2, 4.5 × 107/m2, and 1.2 × 108/m2 No No 2 CR(1 remained in CR for 8 months and the other 1 for 8 weeks)
Brudno et al. 20 CLL, DLBCL, MCL, and ALL 28 From 106/kg to 107/kg 2 (mild chronic GVHD) Fever, tachycardia, and hypotension 8 of 20 patients obtained remission (6 CR and 2 PR)
Zuo et al. 1 ALL 28, 137, and 27 First dose 106/kg and three maintenance (from 0.83 × 106 to 1.65 × 106/kg) No Mild or moderate CRS DFS for 10 months
Grupp et al. 1 ALL 28 1.4 × 106/kg No Fever MRD-negative CR at approximately 1 month and relapse after 2 months
  1. CLL chronic lymphocytic leukemia, DLBCL diffuse large B cell lymphoma, MCL mantle cell lymphoma, ALL acute lymphoblastic leukemia, CAR chimeric antigen receptor, CAR-T chimeric antigen receptors redirected T cells, GVHD graft-versus-host disease, CRS cytokine release syndrome, CR complete remission, PR partial remission, DFS disease-free survival, MRD minimal residual disease